论文部分内容阅读
目的:探讨基质金属蛋白酶MMP-2、MMP-9在乳腺癌中的表达情况及与临床预后的关系。方法:采用组织芯片及免疫组化S-P法检测了183例乳腺癌组织中MMP-2、MMP-9的表达水平。结果:①乳腺癌组织中MMP-2和MMP-9的阳性表达率分别为77·0%(141/183)和65·6%(120/183)。乳腺癌组与良性对照组MMP-2、MMP-9的表达具有显著性差异(P<0·01)。②MMP-2的表达与肿瘤大小有关(P=0·010),与临床TNM分期、淋巴结转移状态、组织学分级密切相关(P均<0·01);MMP-9的表达与组织学分级有关(P=0·012),与肿瘤大小、临床TNM分期、淋巴结转移状态密切相关(P均<0·01);MMP-2和MMP-9的表达与年龄、月经状态、病理类型以及雌孕激素受体状态无关。③MMP-2、MMP-9高表达组10年生存率均低于低表达组。结论:MMP-2、MMP-9均可作为乳腺癌患者预后判断的指标。
Objective: To investigate the expression of matrix metalloproteinase-2 and MMP-9 in breast cancer and its relationship with clinical prognosis. Methods: The expression of MMP-2 and MMP-9 in 183 cases of breast cancer was detected by tissue microarray and immunohistochemical S-P method. Results: ① The positive rates of MMP-2 and MMP-9 in breast cancer tissues were 77.0% (141/183) and 65.6% (120/183), respectively. The expression of MMP-2 and MMP-9 in breast cancer group and benign control group were significantly different (P <0.01). The expression of MMP-2 was related to tumor size (P = 0.010), which was closely related to TNM staging, lymph node metastasis status and histological grade (P <0.01). The expression of MMP-9 was correlated with histological grade (P = 0.012). The expression of MMP-2 and MMP-9 were closely related to tumor size, TNM staging and lymph node metastasis (P <0.01) Hormone receptor status has nothing to do. ③ The 10-year survival rates of MMP-2 and MMP-9 overexpression groups were lower than those of low expression groups. Conclusion: MMP-2 and MMP-9 can be used as indicators of prognosis in patients with breast cancer.